Drug facts
MoleculeVenetoclax (Venclexta)
Generics already compete: 1 maker on the market. 3 A-rated products from 1 maker substitute at the counter.
Venclexta was first approved by the FDA on 04/11/2016 under NDA 208573; the application holder is Abbvie Inc.
Holder Abbvie IncApplication NDA 208573Approved 04/11/2016
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
2,502days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved04/11/2016
Exclusivity ends05/15/2026
Last patent09/06/2033
2017202020232026202920322035
- Latest patent
- 09/06/2033Venclexta Orange Book
- Exclusivity
- 05/15/2026Venclexta Orange Book
02Competition
- Generics
- 1 generic maker Orange Book
- First generic approved
- 05/15/2026 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Venetoclax profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Abbvie Inc Orange Book
- Application
- NDA 208573 Orange Book
- First approved
- 04/11/2016 Orange Book
- Dosage forms
- tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.